Noninvasive Assessment of Liver Fibrosis in NAFLD

Clinical Gastroenterology and Hepatology, Год журнала: 2023, Номер 21(8), С. 2026 - 2039

Опубликована: Апрель 14, 2023

Язык: Английский

---

Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD

Current Obesity Reports, Год журнала: 2024, Номер 13(3), С. 510 - 531

Опубликована: Май 29, 2024

The prevalence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide, making it the leading cause related morbidity and mortality. Currently, biopsy gold standard for assessing individuals with steatohepatitis fibrosis. However, its invasiveness, sampling variability, impracticality large-scale screening has driven search non-invasive methods early diagnosis staging. In this review, we comprehensively summarise evidence on diagnostic performance limitations existing serum biomarkers scores in evaluation steatosis, steatohepatitis,

Язык: Английский

---

WFUMB Guideline/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography

Ultrasound in Medicine & Biology, Год журнала: 2024, Номер 50(8), С. 1071 - 1087

Опубликована: Май 17, 2024

Язык: Английский

---

Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up

Metabolism, Год журнала: 2024, Номер unknown, С. 155800 - 155800

Опубликована: Янв. 1, 2024

Язык: Английский

---

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options

Metabolites, Год журнала: 2024, Номер 14(7), С. 366 - 366

Опубликована: Июнь 28, 2024

Nonalcoholic fatty liver disease (NAFLD) poses an emerging threat topublic health. steatohepatitis (NASH) is reported to be the most rapidly rising cause of hepatocellular carcinoma in western world. Recently, a new term has been proposed: metabolic dysfunction-associated steatotic (MASLD). The introduction this terminology sparked debate about interchangeability these terms. pathogenesis NAFLD/MASLD thought multifactorial, involving both genetic and environmental factors. Among factors, alterations gut microbiota dysbiosis have recently garnered significant attention. In context, review will further discuss gut-liver axis, which refers bidirectional interaction between human liver. Additionally, therapeutic potential probiotics, particularly next-generation probiotics genetically engineered bacteria, explored. Moreover, role prebiotics, synbiotics, postbiotics, phages as well fecal transplantation analyzed. Particularly for lean patients with NAFLD/MASLD, who limited treatment options, approaches that modify diversity composition may hold promise. However, due ongoing safety concerns modulate microbiota, large-scale studies are necessary better assess their efficacy treating NAFLD/MASLD.

Язык: Английский

---

Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(7), С. 3746 - 3746

Опубликована: Март 27, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is influenced by a variety of factors, including environmental and genetic factors. The most significant outcome the alteration free fatty acid triglyceride metabolism. Lipotoxicity, impaired autophagy, chronic inflammation, oxidative stress, as well coexisting insulin resistance, obesity, changes in composition gut microbiota, are also considered crucial factors pathogenesis MASLD. Resveratrol polyphenolic compound that belongs to stilbene subgroup. This review summarises available information on therapeutic effects resveratrol against has demonstrated promising antisteatotic, antioxidant, anti-inflammatory activities cells vitro animal studies. been associated with inhibiting NF-κB pathway, activating SIRT-1 AMPK pathways, normalizing intestinal microbiome, alleviating inflammation. However, clinical studies have yielded inconclusive results regarding efficacy hepatic steatosis or reducing any parameters found MASLD human patients. lack homogeneity between studies, low bioavailability resveratrol, population variability when compared models could be reasons for this.

Язык: Английский

---

Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions

Nutrients, Год журнала: 2024, Номер 16(14), С. 2220 - 2220

Опубликована: Июль 11, 2024

Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting that affects millions of people around the world. It best identified with hepatic fat build-up ultimately leads to inflammation and damage. The classification nomenclature NAFLD have long been controversial topic, until 2020 when group international experts recommended substituting MAFLD (metabolic dysfunction-associated FLD). was then terminologically complemented in 2023 by altering it MASLD, i.e., metabolic steatotic (MASLD). Both MASLD terminologies comprise element disorder, as they offer diagnostic benchmarks are embedded risk factors underlie disease. (as multisystemic disease) provides comprehensive definition includes larger population patients who at morbidity mortality, well adverse cardiovascular diabetes outcomes. highlights risks lean or normal weight individuals, factor has not accentuated discussed previous guidelines. Novel antihyperglycemic agents, anti-hyperlipidemic drugs, lifestyle modifications, nutritional interventions, exercise therapies extensively studied MASLD. Nutrition plays vital role managing both conditions, where centralizing on diet rich whole vegetables, fruits, foods, healthy fats, proteins, specific nutrients (e.g., omega-3 acids fibers) can improve insulin resistance reduce inflammation. Thus, essential understand nutrition these conditions work develop an individualized plan for optimal health. This review discusses prevention strategies NAFLD/MAFLD/MASLD management, particular attention correction.

Язык: Английский

---

Liver diseases: epidemiology, causes, trends and predictions

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Фев. 4, 2025

Abstract As a highly complex organ with digestive, endocrine, and immune-regulatory functions, the liver is pivotal in maintaining physiological homeostasis through its roles metabolism, detoxification, immune response. Various factors including viruses, alcohol, metabolites, toxins, other pathogenic agents can compromise function, leading to acute or chronic injury that may progress end-stage diseases. While sharing common features, diseases exhibit distinct pathophysiological, clinical, therapeutic profiles. Currently, contribute approximately 2 million deaths globally each year, imposing significant economic social burdens worldwide. However, there no cure for many kinds of diseases, partly due lack thorough understanding development these Therefore, this review provides comprehensive examination epidemiology characteristics covering spectrum from conditions manifestations. We also highlight multifaceted mechanisms underlying initiation progression spanning molecular cellular levels networks. Additionally, offers updates on innovative diagnostic techniques, current treatments, potential targets presently under clinical evaluation. Recent advances pathogenesis hold critical implications translational value novel strategies.

Язык: Английский

---

Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK Biobank

Cardiovascular Diabetology, Год журнала: 2025, Номер 24(1)

Опубликована: Янв. 13, 2025

Triglyceride-glucose (TyG) related indices, which serve as simple markers for insulin resistance, have been closely linked to metabolic dysfunction-associated steatotic liver disease (MASLD), cardiovascular (CVD), and mortality. However, the prognostic utility of TyG-related indices in predicting risk CVD mortality among patients with MASLD remains unclear. Data 97,331 patients, a median age 58.0 years free at baseline, were obtained from UK Biobank. The TyG index, along its combination adiposity parameters (i.e. body mass index [BMI], waist circumference [WC], waist-to-height ratio [WHtR]), calculated. Cox proportional hazards models restricted cubic spline (RCS) performed evaluate associations between overall CVD, coronary heart (CHD), stroke, all-cause mortality, Additionally, Harrell's C-index, net reclassification (NRI), integrated discrimination improvement (IDI) used assess predictive performance these indices. Over follow-up 13.56 years, we identified 13,256 cases 10,980 CHD, 2,926 8,809 1,796 Compared lowest quartile participants high had significantly increased incident Specifically, hazard ratios occurring fourth versus first quartiles 1.19 (95% confidence interval: 1.13-1.25) TyG, 1.35 (1.28-1.42) TyG-BMI, 1.33 (1.26-1.40) TyG-WC, 1.39 (1.32-1.46) TyG-WHtR. RCS analyses indicated nonlinear association outcomes (all P values nonlinearity < 0.05), whereas there exhibited linear trends TyG-WHtR > 0.05, except TyG-WC stroke). Furthermore, demonstrated higher NRI, IDI patients. especially TyG-WHtR, significant individuals MASLD. may effective surrogate predictors

Язык: Английский

---

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD

Current Issues in Molecular Biology, Год журнала: 2023, Номер 45(6), С. 4544 - 4556

Опубликована: Май 24, 2023

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been shown to improve glucose and lipid homeostasis, promote weight loss, reduce cardiovascular risk factors. They are a promising therapeutic option for non-alcoholic fatty liver disease (NAFLD), the most common disease, associated with T2DM, obesity, metabolic syndrome. GLP-1RAs approved treatment of T2DM but not NAFLD. Most recent clinical trials suggested importance early pharmacologic intervention in alleviating limiting NAFLD, as well highlighting relative scarcity vitro studies on semaglutide, indicating need further research. However, extra-hepatic factors contribute GLP-1RA results vivo studies. Cell culture models NAFLD can be helpful eliminating extrahepatic effects alleviation hepatic steatosis, modulation metabolism pathways, reduction inflammation, prevention progression severe conditions. In this review article, we discuss role GLP-1 using human hepatocyte models.

Язык: Английский

---